EP0561898A1 - Novel process - Google Patents

Novel process

Info

Publication number
EP0561898A1
EP0561898A1 EP19920900699 EP92900699A EP0561898A1 EP 0561898 A1 EP0561898 A1 EP 0561898A1 EP 19920900699 EP19920900699 EP 19920900699 EP 92900699 A EP92900699 A EP 92900699A EP 0561898 A1 EP0561898 A1 EP 0561898A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
pyridinyl
imidazole
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920900699
Other languages
German (de)
French (fr)
Inventor
Mark A. Smithkline Beecham Pharm. Armitage
Jerome F. Smithkline Beecham Pharm. Hayes
Michael B. Smithkline Beecham Pharm. Mitchell
Garry Dep. Of Chem. Procter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of EP0561898A1 publication Critical patent/EP0561898A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a novel process for preparing fused imidazole derivatives and intermediates used in the process.
  • the present invention provides a process for preparing a compound of the formula (1) :
  • R 1 and R 2 are independently optionally substituted pyridinyl, or optionally substituted phenyl, and A is propane-l,3-diyl or butane-1,4-diyl optionally substituted by one or two c 1 _ 2 al yl groups,
  • R 1 and R 2 are optionally substituted pyridinyl and the other is optionally substituted phenyl.
  • R 1 is optionally substituted pyridinyl and R 2 is optionally substituted phenyl.
  • R 1 and R 2 are as disclosed in the above-noted patents and patent applications.
  • R 1 is pyridinyl optionally substituted by C 1 _ 4 alkyl.
  • R 1 is 4-pyridinyl optionally substituted in the 2-position by C 1 _ 4 alkyl.
  • R 2 is phenyl optionally substituted by C 1 _ alkyl S(0) m wherein m is 0 or 1, or by halo or C- j ⁇ alkox .
  • R 2 is phenyl substituted by C 1 _ 4 alkylthio.
  • R 2 is phenyl substituted in the 4-position by C 1 _ 4 alkylthio.
  • C 1 _ 4 alkyl in the definitions of R 1 and R 2 include methyl, ethyl, propyl and butyl.
  • halo examples include fluoro, chloro, bromo, and iodo.
  • Examples of compounds of the formula (1) which can be prepared by the present process include :
  • the present invention provides a compound of the formula (2) as hereinbefore defined.
  • a compound of the formula (2) can be prepared by reacting in the presence of a suitable base a compound of the formula (3) :
  • R 1 , R 2 , X and A are as hereinbefore defined.
  • Suitable bases include alkyl lithiums such as n-butyl lithium, potassium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium or potassium hydride or potassium hydroxide optionally with a phase transfer catalyst such as tetraoctylammonium bromide, or a suitable mixture thereof, e.g. n-butyl lithium and potassium tert butoxide.
  • a compound of the formula (3) is reacted with an excess of base, suitably 1 to 2 mole equivalents, preferably 1.0 to 1.5 mole equivalents of the base before treatment with a compound of the formula (4) .
  • reaction of a compound of the formula (3) and a compound of the formula (4) is suitably performed in an organic solvent such as tetrahydrofuran, dialkyl ether, dimethylformamide, toluene, dimethylethylidene urea or tetramethylethylenediamine or a suitable mixture thereof within a temperature range of -80° to 100°c, conveniently with cooling initially and then at ambient temperature.
  • organic solvent such as tetrahydrofuran, dialkyl ether, dimethylformamide, toluene, dimethylethylidene urea or tetramethylethylenediamine or a suitable mixture thereof within a temperature range of -80° to 100°c, conveniently with cooling initially and then at ambient temperature.
  • the compound of the formula (2) may be isolated on work-up and then cyclised to a compound of the formula (1) with a suitable base as hereinbefore described.
  • the compound of the formula (2) is not isolated, but is formed jLn situ and cyclised directly to a compound of the formula (1) under the basic conditions of the reaction mixture.
  • the present invention provides a compound of the formula (3) as hereinbefore defined.
  • a compound of the formula (3) is suitably prepared by reacting in the presence of a base a compound of the formula (5) :
  • R 1 is as hereinbefore defined and L is a leaving group, with a compound of the formula (6) :
  • A is as hereinbefore defined. and thereafter if desired converting a compound of the formula (3) wherein X is oxygen to the corresponding compound wherein X is sulphur.
  • bases include potassium hydroxide potassium carbonate, sodium hydride, sodium hydroxide or lithium diisopropylamide.
  • L is halo such as bromo or chloro, tosylate or mesylate.
  • the reaction is suitably performed in a solvent such as tetrahydrofuran, dimethylformamide, tert-butylmethylether, dichloro- methane, toluene, or diethylether, or a mixture thereof, optionally in the presence of water in appropriate cases, for example when using solid potassium hydroxide together with a phase transfer catalyst as the base.
  • the reaction is conveniently performed at ambient or elevated temperature e.g. 30° to 100°C preferably below 60°C.
  • an aqueous solution of an acid addition salt of a compound of the formula (5) is gradually added to a solution of a compound of the formula (6) and the base.
  • a compound of the formula (3) wherein X is oxygen can suitably be converted to the corresponding compound wherein X is sulphur by treatment with a reagent such as Lawesson's reagent (Org. Syn. , 1984, Vol. 62, 158) or Belleau's reagent (Tet. Lett., 1983, 3815).
  • a reagent such as Lawesson's reagent (Org. Syn. , 1984, Vol. 62, 158) or Belleau's reagent (Tet. Lett., 1983, 3815).
  • the present invention provides a process for preparing 6,7-dihydro-2-(4- methylthio-phenyl)3-(4-pyridinyl)-5H-pyrrolo[l,2-a]- imidazole which comprises:
  • a compound of the formula (1) wherein R 1 and/or R 2 is phenyl substituted by C 1 _ 4 alkylthio can be converted to the corresponding compound wherein R 1 or R 2 is phenyl substituted by C 1 _. 4 alkylsulphinyl by treatment with a suitable oxidising agent.
  • suitable oxidising agent include sodium periodate, ceric ammonium nitrate, potassium persulphate, magnesium monoperoxyphthalate, hydrogen peroxide, bromine, N-bromosuccinimide, or sodium perborate.
  • C 1 _ 4 alkylsulphinyl compounds can be readily obtained in the absence of undesired, over-oxidised C 1 _ 4 alkylsulphonyl compounds.
  • the present invention provides a process for preparing a compound of the formula (1) :
  • R 1 and R 2 is phenyl substituted by C 1- alkylsulphinyl, and the other and A are as hereinbefore defined, which comprises reacting the corresponding C 1 _ 4 alkylthio substituted compound with nitric acid.
  • R 2 is phenyl substituted by C 1 _ 4 alkyl- sulphinyl.
  • a particular compound that can be prepared by this process is 6,7-dihydro-2-(4-methylsulphinylphenyl)- 3-(4-pyridinyl)-5H-pyrrolo[l,2-a]imidazole.
  • nitric acid is added to a mixture of the C 1 _ 4 alkylthio compound of formula (1) in a solvent such as water or aqueous sulphuric acid or nitromethane or mixtures thereof, with cooling (e.g. 0 to 5°C) and the reaction mixture is then stirred at ambient temperature.
  • a solvent such as water or aqueous sulphuric acid or nitromethane or mixtures thereof.
  • the reaction mixture was stirred mechanically for a total of 100 minutes between 20-30°C before 4-picolyl chloride hydrochloride (200.0 g, 1.22 mol) in demineralised water (120 ml) was added over 25 minutes. The temperature rose to 40 ⁇ C and was not allowed to rise above this. The reaction mixture was stirred for 120 minutes after this addition and was then filtered through Celite. The reaction flask and filtered solids were washed with THF (400 ml) and the washings combined with the filtrate. Any aqueous material carried over during the filtration was separated before the organic solution was concentrated to a volume of 800 ml by atmospheric distillation of the THF.
  • the solvent was exchanged with ethyl acetate via a put and take distillation where 140 ml solvent was removed and then replaced with 140 ml ethyl acetate. This process was continued until the base temperature reached 77°C. A further 45 ml ethyl acetate was added and the solution cooled to 50°C before 60-80 petrol (87 ml) was added. The product crystallised on cooling to room temperature and after stirring for 3 hours the suspension was cooled to 0-5°C and stirred for a further - 11 -
  • Dichloromethane 1000 ml was added to the aqueous layer and the mixture rapidly stirred. Forty percent w/v sodium hydroxide solution (480 ml) was added slowly ensuring temperature did not exceed 30°C. Upon completion of the addition the mixture was stirred for 15 minutes, allowed to stand for 15 minutes and the layers separated. The aqueous layer was washed with a further 1000 ml of dichloromethane as above.
  • dichloromethane solutions were stirred with distilled water (1000 ml) for 15 minutes, the mixture passed through Celite and allowed to stand for 15 minutes.
  • the dichloromethane solution was run off and heated to reflux. Approximately 1000 ml of dichloro- methane was collected by distillation. Ethyl acetate (1000 ml) was added and distillation continued. 300 ml portions of distillate were collected and 300 ml portions of ethyl acetate added to the pot until the vapour temperature reached 77°C. Distillation was continued to leave a residual volume of 1500 ml.

Abstract

Procédé de préparation du composé répondant à la formule (1), dans laquelle R1 et R2 représentent indépendamment l'un de l'autre pyridinyle éventuellement substitué ou phényle éventuellement substitué, et A représente propane-1,3-diyle ou butane-1,4-diyle éventuellement substitué par un ou deux groupes alkyle C1-2.Process for the preparation of the compound corresponding to formula (1), in which R1 and R2 independently represent one of the other optionally substituted pyridinyl or optionally substituted phenyl, and A represents propane-1,3-diyl or butane-1, 4-diyl optionally substituted with one or two C1-2 alkyl groups.

Description

NOVEL PROCESS
The present invention relates to a novel process for preparing fused imidazole derivatives and intermediates used in the process.
Various fused imidazole derivatives have been disclosed as medicaments in US-A-4719218, EP-A-231622, EP-A-306300 and EP-A-364204. An advantageous process has now been discovered for the synthesis of such derivatives.
Accordingly, the present invention provides a process for preparing a compound of the formula (1) :
wherein
R1 and R2 are independently optionally substituted pyridinyl, or optionally substituted phenyl, and A is propane-l,3-diyl or butane-1,4-diyl optionally substituted by one or two c1_2al yl groups,
which process comprises cyclising a compound of the formula (2) :
or the E-isomer thereof,
wherein X is oxygen or sulphur and R1, R2 and A are as hereinbefore defined.
Suitably one of R1 and R2 is optionally substituted pyridinyl and the other is optionally substituted phenyl.
More suitably R1 is optionally substituted pyridinyl and R2 is optionally substituted phenyl.
Examples of R1 and R2 are as disclosed in the above-noted patents and patent applications.
Suitably R1 is pyridinyl optionally substituted by C1_4alkyl.
Preferably R1 is 4-pyridinyl optionally substituted in the 2-position by C1_4alkyl.
Suitably R2 is phenyl optionally substituted by C1_ alkyl S(0)m wherein m is 0 or 1, or by halo or C-j^alkox .
More suitably R2 is phenyl substituted by C1_4alkylthio. Preferably R2 is phenyl substituted in the 4-position by C1_4alkylthio.
Examples of C1_4alkyl in the definitions of R1 and R2 include methyl, ethyl, propyl and butyl.
Examples of halo include fluoro, chloro, bromo, and iodo.
Examples of compounds of the formula (1) which can be prepared by the present process include :
6,7-dihydro-2-(4-methylthiophenyl)-3-(4-pyridinyl)-5H- pyrrolo[1,2-a]imidazole, 6,7-dihydro-2-(4-fluorophenyl)-3-(4-pyridinyl)-5H- pyrrolo[1,2-a]imidazole,
2-(4-bromophenyl)-6,7-dihydro-3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole,
6,7-dihydro-2-(4-ethylthiophenyl)-3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole,
6,7-dihydro-2-(4-methylthiopheny1)-3-(2-methy1-4- pyridinyl)-5H-pyrrolo[1,2-a]imidazole,
6 ,7-dihydro-2-(4-methylthiophenyl)-3-phenyl-5H- pyrrolo[l,2-a] imidazole, or 6,7,8,9-tetrahydro-2-(4-methylthiophenyl)-3-pyridyl-5H- pyrido[l,2-a] imidazole.
Compounds of the formula (1) wherein R2 is phenyl substituted by C1«4alkylthio, e.g. 6,7-dihydro-2- (4-methylthiophenyl)-3-(4-pyridinyl)-5H-pyrrolo[l,2-a]- imidazole, are of particular interest. They are inhibitors of the 5-lipoxygenase pathway and also useful intermediates since they can be oxidised to their C1_.4alkylsulphinyl analogues. - A -
In another aspect the present invention provides a compound of the formula (2) as hereinbefore defined.
A compound of the formula (2) can be prepared by reacting in the presence of a suitable base a compound of the formula (3) :
with a compound of the formula (4)
R2CN (4)
wherein R1, R2, X and A are as hereinbefore defined.
Examples of suitable bases include alkyl lithiums such as n-butyl lithium, potassium tert-butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium or potassium hydride or potassium hydroxide optionally with a phase transfer catalyst such as tetraoctylammonium bromide, or a suitable mixture thereof, e.g. n-butyl lithium and potassium tert butoxide. Conveniently a compound of the formula (3) is reacted with an excess of base, suitably 1 to 2 mole equivalents, preferably 1.0 to 1.5 mole equivalents of the base before treatment with a compound of the formula (4) .
The reaction of a compound of the formula (3) and a compound of the formula (4) is suitably performed in an organic solvent such as tetrahydrofuran, dialkyl ether, dimethylformamide, toluene, dimethylethylidene urea or tetramethylethylenediamine or a suitable mixture thereof within a temperature range of -80° to 100°c, conveniently with cooling initially and then at ambient temperature.
The compound of the formula (2) may be isolated on work-up and then cyclised to a compound of the formula (1) with a suitable base as hereinbefore described.
Preferably, however, the compound of the formula (2) is not isolated, but is formed jLn situ and cyclised directly to a compound of the formula (1) under the basic conditions of the reaction mixture.
In a further aspect the present invention provides a compound of the formula (3) as hereinbefore defined.
A compound of the formula (3) is suitably prepared by reacting in the presence of a base a compound of the formula (5) :
R^-C^L (5)
or an acid addition salt thereof, wherein R1 is as hereinbefore defined and L is a leaving group, with a compound of the formula (6) :
wherein A is as hereinbefore defined. and thereafter if desired converting a compound of the formula (3) wherein X is oxygen to the corresponding compound wherein X is sulphur.
Examples of bases include potassium hydroxide potassium carbonate, sodium hydride, sodium hydroxide or lithium diisopropylamide. Suitably L is halo such as bromo or chloro, tosylate or mesylate. The reaction is suitably performed in a solvent such as tetrahydrofuran, dimethylformamide, tert-butylmethylether, dichloro- methane, toluene, or diethylether, or a mixture thereof, optionally in the presence of water in appropriate cases, for example when using solid potassium hydroxide together with a phase transfer catalyst as the base. The reaction is conveniently performed at ambient or elevated temperature e.g. 30° to 100°C preferably below 60°C. Preferably an aqueous solution of an acid addition salt of a compound of the formula (5) is gradually added to a solution of a compound of the formula (6) and the base.
A compound of the formula (3) wherein X is oxygen can suitably be converted to the corresponding compound wherein X is sulphur by treatment with a reagent such as Lawesson's reagent (Org. Syn. , 1984, Vol. 62, 158) or Belleau's reagent (Tet. Lett., 1983, 3815).
In a particular embodiment the present invention provides a process for preparing 6,7-dihydro-2-(4- methylthio-phenyl)3-(4-pyridinyl)-5H-pyrrolo[l,2-a]- imidazole which comprises:
a) reacting an acid addition salt of 4-picolylchloride with a basic solution of 2-pyrrolidinone to form 1-(4-picolyl)-2-pyrrolidinone; b) reacting in the presence of a suitable base l-(4-picolyl)-2-pyrrolidinone with 4-methylthio- benzonitrile to form Z-1-amino-l-(4-methylthiophenyl)-2- (4-pyridyl)-2-{l-(2-oxo-pyrrolidinyl)>ethene which is cyclised n situ to form the desired compound.
If desired a compound of the formula (1) wherein R1 and/or R2 is phenyl substituted by C1_4alkylthio can be converted to the corresponding compound wherein R1 or R2 is phenyl substituted by C1_.4alkylsulphinyl by treatment with a suitable oxidising agent. Examples of such agents include sodium periodate, ceric ammonium nitrate, potassium persulphate, magnesium monoperoxyphthalate, hydrogen peroxide, bromine, N-bromosuccinimide, or sodium perborate.
It has now been discovered that surprisingly a particularly selective oxidising agent for the above-noted oxidation is nitric acid. The desired
C1_4alkylsulphinyl compounds can be readily obtained in the absence of undesired, over-oxidised C1_4alkylsulphonyl compounds.
Thus, in a further aspect the present invention provides a process for preparing a compound of the formula (1) :
wherein one or both of R1 and R2 is phenyl substituted by C1- alkylsulphinyl, and the other and A are as hereinbefore defined, which comprises reacting the corresponding C1_4alkylthio substituted compound with nitric acid.
Suitably R2 is phenyl substituted by C1_4alkyl- sulphinyl.
A particular compound that can be prepared by this process is 6,7-dihydro-2-(4-methylsulphinylphenyl)- 3-(4-pyridinyl)-5H-pyrrolo[l,2-a]imidazole.
Suitably concentrated nitric acid is added to a mixture of the C1_4alkylthio compound of formula (1) in a solvent such as water or aqueous sulphuric acid or nitromethane or mixtures thereof, with cooling (e.g. 0 to 5°C) and the reaction mixture is then stirred at ambient temperature.
Example 1
6-7-Dihydro-2- (4-methylthiophenyl)-3-(4-pyridinyl)- 5H-pyrrolo r1.2-a] imidazole
a) To a vigorously stirred suspension of potassium hydroxide (341.0 g, 6.09 mol) and tetraethylammonium bromide (51.2 g, 0.24 mol) in tetrahydrofuran (THF) (2.0 1) was added 2-pyrrolidinone (97.2 ml, 1.28 mol) at 20βC. A thick white slurry formed and the temperature rose to 27°C within 30 minutes.
The reaction mixture was stirred mechanically for a total of 100 minutes between 20-30°C before 4-picolyl chloride hydrochloride (200.0 g, 1.22 mol) in demineralised water (120 ml) was added over 25 minutes. The temperature rose to 40βC and was not allowed to rise above this. The reaction mixture was stirred for 120 minutes after this addition and was then filtered through Celite. The reaction flask and filtered solids were washed with THF (400 ml) and the washings combined with the filtrate. Any aqueous material carried over during the filtration was separated before the organic solution was concentrated to a volume of 800 ml by atmospheric distillation of the THF. The solution was cooled to 20°C at which point 60-80 petrol (500 ml) was added. The solution was stirred for 10 minutes when a further 500 ml quantity of 60-80 petrol was added. This mixture was stirred for a further 10 minutes when a final 600 ml quantity of 60-80 petrol was added. The mixture was cooled to 5°C for 16 hours before the product was isolated by filtration, washed with 60-80 petrol (400 ml) , and dried at 40°C, 100 mmHg for 24 hours. Hence 1-(4-picolyl)-2-pyrrolidinone 186.0 g (86%) was obtained as a pale brown granular crystalline solid; m.p. 82-84°C; M+, 176.0947. C10H12 N2° requires 176.0950; m/z 176, (M+) , 147 (M+ - C2H5) , 119 (147-CO) and ' 93 (119 - HCN) ; V maximum (KBr) 2950, 1690 (C=0) , 1600, 1450, 1420, 1300 and 1280 cm"1; SH(270 MHz, CDC13) 1.85 (2H, m, -CH2CH2CH2-) , 2.20 (2H, t, -CH-,C(0) , 3.10 (2H, t, -C^CI^N R1) , 4.25 (2H, S, PyCH2-) , 6.95 (2H, m, Ar(3,5)) and 8.30 (2H, m, Ar(2,6).
b) To a solution of 1-(4-picolyl)-2-pyrrolidinone (20.0 g, 0.114 mol) in dry THF (260 ml) was added n-butyllithium (50.0 ml of a 2.5 M solution in hexane 0.125 mol) at 0 to -10°C. The addition required 10 minutes. Potassium tert-butoxide (12.7 g, 0.114 mol) in THF (65 ml) was then added at 0 to -10°C over 5 minutes and the resultant golden yellow suspension stirred for 10 minutes. At this point 4-methylthiobenzonitrile (18.6 g, 0.125 mol) in THF (31 ml) was added over 5 minutes at 0β to -10°C. When the addition was complete the reaction mixture was allowed to warm to ambient temperature over 30 minutes and was maintained at this temperature for 30 minutes. After this period the reaction mixture was heated under reflux for 120 minutes and then cooled to 30°C before demineralised water (80 ml) was added. The resultant mobile solution was stirred for 30 minutes and the aqueous layer then allowed 30 minutes to separate before it was removed.
The solvent was exchanged with ethyl acetate via a put and take distillation where 140 ml solvent was removed and then replaced with 140 ml ethyl acetate. This process was continued until the base temperature reached 77°C. A further 45 ml ethyl acetate was added and the solution cooled to 50°C before 60-80 petrol (87 ml) was added. The product crystallised on cooling to room temperature and after stirring for 3 hours the suspension was cooled to 0-5°C and stirred for a further - 11 -
2 hours. The product was then isolated by filtration, washed with 60-80 petrol (40 ml) and then dried at 40°C, 100 mmHg for 24 hours. Hence 6,7-dihydro-2-(4-methyl¬ thiophenyl)-3-(4-pyridinyl)-5H-pyrrolo [1,2-a] imidazole was obtained as a pale yellow crystalline solid; 17.6 g, 50%; m.p. 172°C; δH (270MHz, CDC13) 2.50 (3H, S, -SJfe) , 2.70 (2H, m, -CH2Cfi2, CH2-) 3.00 (2H, t, -C^CHg^ R1) , 4.05 (2H, t, -C^C^CHjN 1) , 7.20 (2H, m, MeS r) , 7.30 (2H,m, 3,5-Py), 7.50 (2H, m. Me S Ar) and 8.60 (2H, m, 2,6-Py).
Example 2
6.7-Dihydro-2-(4-methylthiophenyl>-3- (4-pyridinyl)- 5H-pyrrolo flf2-a] imidazole
a) To a solution of 1-(4-picolyl)-2-pyrrolidinone (2.01 g, 11.4 mmol) in THF (285 ml) was added jn-butyllithium (8.70 ml of a 2.5M solution in hexane,
21.7 mmol) at -70°C. The resultant yellow suspension was stirred for 90 minutes between -30 to -70°C before 4-methylthiobenzonitrile (2.72 g, 18.3 mmol) in THF (40 ml) was added at -65°C. The reaction mixture was stirred with warming to room temperature over 15 minutes and was then stirred for a further 21 hours. After this time ammonia (720μl of a 35% w/w aqueous solution) was added which caused the reaction mixture to change from blood red to yellow in colour. This solution was stirred for 30 minutes before the solvent was removed in vacuo and the residue chromatographed on silica gel using ethyl acetate: triethylamine - 96:4 as eluant. Hence Z-l-amino-1-(4-methylthiophenyl)-2-(4-pyridyl)-2-{l- (2-oxo-pyrrolidinyl))ethene (1.2 g, 32%) was obtained as a free flowing yellow powder, m.p. 220-222°C (from ethyl acetate) M+ 325.1271. C18H19N30S re*3ui-res 325.1249. V maximum (nujol mull) 3500-3300 (N-H), 1669 (C-0) , 1632 (C-C) and 1566 cm"1; δH (270 MHZ, d6-DMSO) 2.15 (2H, m, -CH2CH2CH2-) , 2.35 (2H, t, -CH2CH2CH2C(0)-), 2.50 (3H, s, -SMe) , 3.50 (2H, t, -CH2CH2Cfi2C(0)-), 5.70 (2H, s, -NH2), 6.50 (2H, m, 3,5-Py), 7.25 (4H, m, MeS r) and 8.05 (2H, m, 2r6-Py); m/Z 325(M+), 308 (M-NH3) , 268 (M-C3H50) and 150 (C8H8NS) .
b) To a suspension of Z-l-amino-1-(4-methylthiophenyl)- 2-(4-pyridyl)-2-{l-(2-pyrrolidinoyl)}ethene (114 mg, 0.351 mmol) in THF (8.8 ml) was added n-butyllithium (249 μl of a 2.5 M solution in hexane, 0.491 mmol) at -40°C. The resultant dark red solution was allowed to warm to room temperature over 30 minutes and was then stirred at this temperature for 19 hours. After this time the colour changed to light yellow. At this point the reaction mixture was assayed by HPLC and found to contain the title compound 88 mg, 82%.
2- (4-Fluorophenyl)-6.7-dihvdro-3-f -pyridinyl)-5H-pyrrolo
To a solution of 1-(4-picolyl)-2-pyrrolidinone (56 mg, 0.318 mmol) in dry THF (8 ml) was added n-butyllithium (472 μl of a 1.0 M solution in hexane,
0.477 mmol) at -80°C. The resultant cloudy bright yellow solution was stirred between -50 to -80°C for 50 minutes before p-fluorobenzonitrile (61 mg, 0.807 mmol) was added in THF (3 ml) at -80°C. The reaction mixture was then allowed to warm to room temperature when it became dark red. It was stirred for 18 hours before the solvent was removed in vacuo and the residue chromatographed on silica gel using ethyl acetate:methanol - 4:1 as eluant. Hence the title compound was obtained (7 mg, 7%) which had identical spectroscopic properties to an authentic sample (see Example 15 of EP-A-231622) .
Example 4
2- -Bromophenvl -6.7-dihvdro-3-f4-pyridinyli-5H-pyrrolo-
To a solution of 1-(4-picolyl)-2-pyrrolidinone (2.66 g, 15.1 mmol) in dry THF (76 ml) was added n-butyllithium (7.26 ml of a 2.5 M solution in hexane, 18.1 mmol) at -40°C. A solution of potassium tert butoxide (1.69 g, 15.1 mmol) in THF (8.5 ml) was then added and the resultant golden yellow suspension stirred at -40 °C for 10 minutes. At this point a solution of 4-bromobenzonitrile (5.50 g, 30.2 mmol) in THF (50 ml) was added at -40βC and the reaction mixture then allowed to warm to room temperature. After stirring for 18 hours the reaction mixture was concentrated to dryness and the residue chromatographed on silica gel using ethyl acetate: ethanol - 5:1 as eluant. Hence the title compound was obtained as a yellow crystalline solid (0.71 g, 14%); M+ 339.0371. C17H14 3 79Br requires 339.0371 M+ 341.0387. C17H14N3 81Br requires 341.0351. δH (270 MHz, CDC13) 2.65 (2H, m, -CH2,CH2CH2-) , 3.00 (2H, t,
-CH2CH2CH2NRR') , 4.00 (2H, t, -CH2CH2CH2NRR') , 7.25 (2H, m, 3,5-Py), 7.40 (4H, m, Br-Ar) and 8.60 (2H, m, 2,6-Py); m/Z 339 (M+) , 341 (M+) 259 (M-HBr) , 310 (M-C2H5) and 312 (M-C2H5) . 6.7-Dihydro-2-(4-methylsulphinylphenyl)-3- (4-pyridinyl)-
6,7-Dihydro-2-(4-methylthiophenyl)-3-(4-pyridinyl)- 5H-pyrrolo[l,2-a]imidazole (100.0 g) was added to distilled water (300 ml) and the mixture cooled to 0-5βC with rapid stirring. Concentrated nitric acid (-70% w/v) (300 ml) was added at such a rate so as to keep the reaction temperature below 25βC. upon completion of the addition the mixture was stirred at ambient temperature for three hours during which time a clear solution was obtained.
Distilled water (300 ml) was added, mixture stirred for 2 minutes and dichloromethane (300 ml) added. Mixture stirred for 15 minutes, layers allowed to separate for 15 minutes and dichloromethane solution run off. Aqueous washed again with 300 ml of dichloromethane as above.
Dichloromethane (1000 ml) was added to the aqueous layer and the mixture rapidly stirred. Forty percent w/v sodium hydroxide solution (480 ml) was added slowly ensuring temperature did not exceed 30°C. Upon completion of the addition the mixture was stirred for 15 minutes, allowed to stand for 15 minutes and the layers separated. The aqueous layer was washed with a further 1000 ml of dichloromethane as above.
The combined dichloromethane solutions were stirred with distilled water (1000 ml) for 15 minutes, the mixture passed through Celite and allowed to stand for 15 minutes. The dichloromethane solution was run off and heated to reflux. Approximately 1000 ml of dichloro- methane was collected by distillation. Ethyl acetate (1000 ml) was added and distillation continued. 300 ml portions of distillate were collected and 300 ml portions of ethyl acetate added to the pot until the vapour temperature reached 77°C. Distillation was continued to leave a residual volume of 1500 ml.
The mixture was allowed to cool to room temperature over 2 hours and was then cooled to 0°C over 2 hours. After stirring at 0°C for 2 hours the product was collected by filtration and washed with 300 ml portion of cold ethyl acetate. Product dried at 80βC under vacuum for 24 hours, m.p. 164-166°C.
Yields typically 80-85%.
Example 6
6.7-Dihyd_ro-2-(4-methylthiophenyl)-3-phenyl-5H- PVrrolori.2-a1 ■hn-idasnle
a) A suspension of potassium hydroxide (32.75 g, 0.585 mol), tetrabutyl ammonium bromide (7.53 g, 0.023 mol) and 2-pyrrolidinone (10.44 g, 0.123 mol) in THF (300 ml)was stirred at room temperature for 2 hours before benzyl bromide (20.00 g, 0.117 mol) was added. On addition of benzyl bromide the temperature rose to 40°C over 15 minutes and the reaction mixture was maintained at this temperature by cooling in an ice bath. Once the temperature began to fall the ice bath was removed and the reaction mixture stirred at room temperature for 18 hours. Water (40 ml) was then added and the 2-phase system stirred for 15 minutes. After this time the lower aqueous layer was separated and the organic layer was dried (MgS0 ) and concentrated in vacuo. The residue was chromatographed in silica gel using ethyl acetate as eluant. Hence l-benzyl-2-pyrrolidinone (9.46 g, 50%) was obtained as a clear viscous oil; V max. (thin film) 2900, 1690, 1420, 1280 and 1260 cm"1; δH (270MHz, CDC13) 2.00 (2H,m,-CH2CH2CH2-) , 2.40 (2H,t -C(O) CH2-) , 3.20 (2H,t,RR1NCH2) , 4.40
-(2H,s,PhCH2-) and 7.2-7.4 (5H,m,Ph) ; m/z.175 (M+) and 91.
b) To a solution of l-benzyl-2-pyrrolidinone (1.00 g, 5.71 mmol) in THF (25 ml) was added n-butyllithium
(2.70 ml of a 2.5M solution in hexane, 6.75 mmol) at -40°C. The resultant yellow-brown mixture was stirred for 5 minutes before potassium tert-butoxide (0.687 g, 6.13 mmol) in THF (3.5 ml) was added. The colour changed to red and then back to yellow-brown. The mixture was stirred at -25βC for 15 minutes before 4-methylthio- benzonitrile (1.01 g, 6.78 mmol) in THF (20. ml) was added. The colour became dark red after approximately 30 minutes. The reaction mixture was then allowed to warm to room temperature and was stirred for 18 hours before water (3.0 ml) was added. The 2-phase system was stirred for 15 minutes before the lower aqueous layer was separated. The organic layer was concentrated in vacuo and the residue chromatographed on silica gel using ethyl acetate : triethylamine - 96:4 as eluant. Hence the title compound (0.05 g, 3%) was obtained as a solid residue; δH (270MHz) 2.40 (3H,s,-SMe), 2.55 (2H,m,-CH2CH2CH2-) , 2.95 (2H,t) , 3.85 (2H,t) and 7.00-7.40 (9H,m) ; m/z 306 (M+) .
Example 7
6.7.8.9-Tetrahydro-2-f4-methylthiophenyl)-3-pyridyl-5H- pyridor .2-al imidazole
a) A suspension of 2-piperidone (31.73 g, 0.321 mol), potassium hydroxide (85.37 g, 1.524 mol) and tetraethylammonium bromide (12.80 g, 0.061 mol) was stirred in THF (500 ml) at room temperature for 2 hours. After this time 4-chloromethylpyridine (50.00 g, 0.305 mol) in water (30.0 ml) was added over 10 minutes. The temperature rose to 40°C and was not allowed to rise higher. The exotherm ceased after 30 minutes and the temperature was allowed to fall to room temperature. After stirring for l hour at room temperature further potassium hydroxide (34.15 g, 0.610 mol) was added which caused the temperature to rise to 30°C. The suspension was stirred for 18 hours at room temperature after which time it was filtered and the lower aqueous layer separated. The solution was concentrated in vacuo to leave a viscous oil which was distilled using a Kugelrohr oven, b.p. 60-80βC/0.005 mm. The distillate crystallised on standing at room temperature. Hence 1-(4-picolyl)-2- piperidone was obtained 10.00 g, 17%) m.p. 79-82°C (from ether), δH (270 MHz, CDC13) 1.90 (4H,m, -CH2CH2CH2CH2-) , 2.55 (2H,m) , 3.25 (2H,m) , 4.7 (2H,s), 7.20 (2H,d) and 8.60 (2H,d) .
b) To a solution of 1-(4-picolyl)-2-piperidone (7.00 g, 36.8 mmol) in THF (91 ml) was added n-butyllithium (16.21 ml of a 2.5M solution in hexane, 40.5 mmol) at -10 - 0°C. Potassium tert-butoxide 4.13 g, 36.9 mmol) in THF (20 ml) was added to the resultant bright yellow suspension and after stirring at -10βC for 15 minutes, 4-methylthiobenzonitrile (5.50 g, 36.9 mmol) was added in THF (10 ml) . The reaction mixture became dark red and was stirred at room temperature for 18 hours. After this time, water (18 ml) was added and the 2-phase system stirred for 20 minutes before the lower aqueous layer was removed. The organic layer was concentrated to dryness and the resultant yellow solid residue dissolved in hot ethyl acetate (100 ml) . The solution was filtered and hexane (18 ml) added. On cooling to 5°C, the product crystallised and after 24 hours was filtered and dried under high vacuum. Hence the title compound was obtained as a yellow crystalline solid (6.63 g, 56%), m.p. (from ethyl acetate-hexane) 205-206βC, V max, (KBr) 2950, 1600 and 1470 cm"1 δH (270MHz, CDC13)2.05 (4H,m,-CH2CH2CH2CH2-) , 2.55 (2H,S,SJle) , 3.20 (2H,m) , 3.90 (2H,m) , 7.20 (2H,d) , 7.35 (2H,d) , 7.45 (2H,d) and 8.80 (2H,d) ; δc (67.80 MHz, CDC13 16.0, 21.0, 23.3, 25.3, 44.5, 124.5, 125.2, 127.9, 131.0, 137.6, 138.3, 139.3, 146.2 and 150.7; BlΑ 321 (M+) and 306.
Example 8
6.7-Dihvdro-2- (4-methylthiopheny1)-3-f4-pyridinyl ) - 5H-pyrrolo ri.2-a1 imidazole
a) To a solution of 1-(4-picolyl)-2-pyrrolidinone (20.00 g, 0.114 mol) in 1,4-dioxane (260 ml) was added phosphorous pentasulphide (25.23 g, 0.114 mol) followed by further 1,4-dioxane (140 ml). The mixture was heated under reflux for 2.5 hours, cooled to room temperature and the solvent decanted from the solid residue. The solid was dissolved in ammonia solution (800 ml of a 35% aqueous solution) and water (500 ml) . The solution was extracted with dichloromethane (4 x 800 ml) and the combined organic extracts concentrated to dryness. The residue was chromatographed on silica gel using ethyl acetate : hexane : triethylamine - 16:3:1 as eluant. Hence 1-(4-picolyl)-2-thiopyrrolidinone was obtained (4.66 g, 21%) as a white crystalline solid, m.p. 125-128°C (from ether); v maχ (KBr) 2950, 1600, 1520, 1420, 1290 and 1240 cm-1, δH (270MHz, CDC13) 2.00 (2H,m, -CH2CH2CH2-) , 3.00(2H,t), 3.70 (2H,t) , 5.00
(2H,s,PyCH2-) 7.25 (2H,d,H-3 and H-5 on pyridyl ring) and 8.55 (2H,d,H-2 and H-4 on pyridyl ring); m/z 192 (M+) and 107. b) To a solution of 1-(4-picolyl)-2-thiopyrrolidinone (0.500 g, 2.60 mmol) in THF (15.0 ml) was added n-butyllithium (1.15 ml of a 2.5 M solution in hexane, 2.88 mmol) at -10°C. The resultant dark red-brown solution was stirred at -10°C for 20 minutes before
4-methylthiobenzonitrile (0.580 g, 3.89 mmol) was added in 1.0 ml THF. The reaction mixture was allowed to warm to room temperature and was then heated under reflux for 2.5 hours. After this time the solution was assayed for the required product by h.p.l.c. and shown to contain the title compound (104 mg, 13%) .

Claims

Claims :
1. A process for preparing a compound of the formula (1) :
wherein
R1 and R2 are independently optionally substituted pyridinyl, or optionally substituted phenyl, and A is propane-1,3-diyl or butane-l,4-diyl optionally substituted by one or two C1_2alkyl groups,
which process comprises cyclising a compound of the formula (2) :
or the E-isomer thereof,
wherein X is oxygen or sulphur and R1, R2 and A are as hereinbefore defined.
2. A process according to claim 1 wherein one of R1 and R2 is optionally substituted pyridinyl and the other is optionally substituted phenyl.
3. A process according to claim 1 or 2 wherein R1 is pyridinyl optionally substituted by C1_4alkyl.
4. A process according to claim 3 wherein R1 is 4-pyridinyl optionally substituted in the 2-position by
C1_ alkyl.
5. A process according to any one of claims l to 4 wherein R2 is phenyl optionally substituted by C-^alkyl S(0)m wherein m is o or 1, or by halo, or C1- alkoxy.
6. A process according to any one of claims 1 to 5 wherein R2 is phenyl substituted by C1_4alkylthio.
7. A process according to claim 6 wherein R2 is phenyl substituted in the 4-position by C1_4alkylthio.
8. A process according to claim l wherein a compound of the formula (l) is :
6,7-dihydro-2-(4-methylthiophenyl)-3-(4-pyridinyl)-5H- pyrrolo[1,2-a]imidazole,
6 ,7-dihydro-2-(4-fluorophenyl)-3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole, 2-(4-bromophenyl)-6,7-dihydro-3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole,
6,7-dihydro-2-(4-ethylthiophenyl)-3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole,
6,7-dihydro-2-(4-methylthiophenyl)-3-(2-methyl-4- pyridinyl)-5H-pyrrolo[1,2-a]imidazole,
6,7-dihydro-2-(4-methylthiophenyl)-3-phenyl-5H- pyrrolo[l,2-a] imidazole, or
6,7,8,9-tetrahydro-2-(4-methylthiophenyl)-3-pyridyl-5H- pyrido[l,2-a] imidazole
9. A compound of the formula (2) :
or the E-isomer thereof,
wherein R1, R2, X and A are as defined in any one of claims 1 to 7.
10. A process for preparing a compound of the formula (2) as defined in claim 9 which comprises reacting in the presence of a suitable base a compound of the formula (3) :
X
with a compound of the formula (4) :
R2CN (4)
when R1, R2, X and A are as hereinbefore defined.
11. A process according to claim 10 wherein the base is selected from an alkyllithium, potassium tert butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium or potassium hydride or potassium hydroxide, or a mixture thereof.
12. A process according to claim 10 or 11 wherein the compound of the formula (2) is not isolated but is cyclised directly to a compound of the formula (1) as defined in any one of claims l to 8.
13. A compound of the formula (3) :
wherein R1, X and A are as defined in any one of claims 1 to 7.
14. A process for preparing a compound of the formula (3) as defined in claim 13 which comprises reacting in the presence of a base a compound of the formula (5) :
R^-CH-jL (5)
or an acid addition salt thereof, wherein R1 is as hereinbefore defined and L is a leaving group,
with a compound of the formula (6) :
wherein A is as hereinbefore defined. and thereafter if desired converting a compound of formula (3) wherein X is oxygen to the corresponding compound wherein X is sulphur.
15. A process for preparing a compound of the formula (1) as defined in any one of claims 1 to 8 which comprises :
a) reacting in the presence of a base a compound of the formula (5) :
R-'-CH-.L (5)
or an acid addition salt thereof, wherein R1 is as hereinbefore defined and L is a leaving group, with a compound of the formula (6) :
where A is as hereinbefore defined, to form a compound of the formula (3) :
(3)
wherein X is oxygen and R1 and A are as hereinbefore defined,
and thereafter if desired converting this to the corresponding compound wherein X is sulphur;
b) reacting in the presence of a suitable base a compound of the formula (3) as hereinbefore defined with a compound of the formula (4)
R2CN (4)
wherein R2 is as hereinbefore defined, to form a compound of the formula (2) :
or the E-isomer thereof,
where R >1x, τR>2**-, X and A are as hereinbefore defined; and
c) cyclising a compound of the formula (2) as hereinbefore defined.
16. A process according to claim 15 which comprises;
a) reacting an acid addition salt of 4-picolylchloride with a basic solution of 2-pyrrolidinone to form 1-(4-picolyl)-2-pyrrolidinone; and b) reacting in the presence of a suitable base 1-(4-picolyl)-2-pyrrolidinone with 4-methylthio¬ benzonitrile to form Z-l-amino-1-(4-methylthiophenyl)-2- (4-pyridyl)-2-{l-(2-oxo-pyrrolidinyl)}ethene which is cyclised in situ to form 6,7-dihydro-2-(4- methylthiophenyl)3-(4-pyridinyl)-5H-pyrrolo[1,2-a]- imidazole.
17. A process according to claim 6 or 16 or claim 1 or 2 when R1 and/or R2 is phenyl substituted by
C1_4alkylthio wherein the compound of the formula (1) is oxidised to the corresponding C1_4alkylsulphinyl compound with a suitable oxidising agent.
18. A process for preparing a compound of the formula (1) :
wherein one or both of R1 and R2 is phenyl substituted by C1__4alkylsulphinyl, and the other and A are as defined in any one of claims 1 to 7 which comprises reacting the corresponding substituted C1_4alkylthio compound with nitric acid.
19. A process according to claim 18 wherein 6,7- dihydro-2-(4-methylsulphinylphenyl)3-(4-pyridinyl)-5H- pyrrolo[l,2-a]imidazole is produced.
EP19920900699 1990-12-12 1991-12-12 Novel process Withdrawn EP0561898A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909026926A GB9026926D0 (en) 1990-12-12 1990-12-12 Novel process
GB9026926 1990-12-12

Publications (1)

Publication Number Publication Date
EP0561898A1 true EP0561898A1 (en) 1993-09-29

Family

ID=10686858

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920900699 Withdrawn EP0561898A1 (en) 1990-12-12 1991-12-12 Novel process

Country Status (5)

Country Link
EP (1) EP0561898A1 (en)
JP (1) JPH06503561A (en)
AU (1) AU9060091A (en)
GB (1) GB9026926D0 (en)
WO (1) WO1992010499A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
HUP0400266A2 (en) 2001-06-21 2004-08-30 Smithkline Beecham Corp. Pharmaceutical compositions containing imidazo[1,2-a]pyridine derivatives, and their use for the prophylaxis and treatment of herpes viral infections
JP2005508955A (en) 2001-10-05 2005-04-07 スミスクライン ビーチャム コーポレーション Imidazo-pyridine derivatives for use in the treatment of herpesvirus infections
JP2005534618A (en) 2002-03-28 2005-11-17 エーザイ株式会社 7-azaindole as a C-JUNN-terminal kinase inhibitor for neurodegenerative diseases
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD234001A1 (en) * 1985-01-11 1986-03-19 Univ Berlin Humboldt PROCESS FOR THE PREPARATION OF THIOCARBONYLIMIDOYL LACTAMENE
US5002941A (en) * 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9210499A1 *

Also Published As

Publication number Publication date
JPH06503561A (en) 1994-04-21
AU9060091A (en) 1992-07-08
WO1992010499A1 (en) 1992-06-25
GB9026926D0 (en) 1991-01-30

Similar Documents

Publication Publication Date Title
KR900008566B1 (en) Process for the preparation of substituted bicyclic compounds
JP3713724B2 (en) Method for producing imidazopyridine derivative
Lepifre et al. Palladium-catalyzed coupling of vinyl phosphates with aryl or heteroaryl boronic acids. Application to the synthesis of substituted nitrogen containing heterocycles
IL168884A (en) Process for the preparation of pyrimidine compounds
KR20080024538A (en) Processes for the manufacture of rosuvastatin and intermediates
EP1549643A2 (en) Method for preparing fused oxazinones from ortho-amino aromatic carboxylic acid and a carboxylic acid in the presence of a sulfonyl chloride and pyridine
WO2009144391A1 (en) Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[l,2- α] pyridines, and preparation and therapeutic use thereof
EP0561898A1 (en) Novel process
HU199472B (en) Process for producing dihydroimidazo-pyrrolopyridine,-quinoline, -thienopyridine derivatives
Hibino et al. A new route to the pyridine nucleus fused to some heterocycles
HUT68757A (en) Process for regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid
US4347186A (en) Process for preparing 5-aroyl 1,2-dihydro-3-H pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein
US4347187A (en) Process for preparing 5-aroyl 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and novel intermediates therein
US5446159A (en) Process for preparing imidazopyridine derivatives
EP0271225B1 (en) Indene derivatives and methods
JPH07188269A (en) Phoshonate diester derivative
JP2599610B2 (en) Process for producing 2β-substituted methylpenicillin derivatives
US4458081A (en) 5-Aroyl 1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1,1-decarboxylates
Sato et al. Studies on pyrazines. 35. An improved synthesis of bromopyrazines from hydroxypyrazines
US3879413A (en) Process for the production of 6-phenyl-4-H-s-triazolo {8 4,3-a{9 {8 1,4{9 benzodiazepines
EP0203787A2 (en) Process for preparing pyridyl-substituted imidazo[2,1-b]thiazoles and thiazines
EP0971919B1 (en) Process for preparation of 4h-4-oxo-quinolizine-3-carboxylic acid derivatives
US5008390A (en) Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and corresponding thiazines
CZ284321B6 (en) Process for preparing phytostigminecarbamate derivatives
US4803279A (en) 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19960314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960925